Thymosin β4, a potential marker of malignancy and prognosis in hepatocellular carcinoma

References

• Dhir M, Melin AA, Douaiher J, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. 2016;263(6):1112–1125.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576.
   PubMed Web of Science ®Google Scholar
• Khera L, Paul C, Kaul R. Hepatitis C virus mediated metastasis in hepatocellular carcinoma as a therapeutic target for cancer management. Curr Drug Metab. 2018;19(3):224–235.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015;19(2):309–323.
   PubMed Web of Science ®Google Scholar
• Volk ML, Hernandez JC, Su GL, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP and AFP-L3. Cancer Biomark. 2007;3(2):79–87.
   PubMedGoogle Scholar
• De Stefano F, Chacon E, Turcios L, et al. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018;50(11):1115–1123.
   PubMedGoogle Scholar
• Arrieta O, Cacho B, Morales-Espinosa D, et al. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer. 2007;7:28.
   PubMed Web of Science ®Google Scholar
• Pierson J, Norris JL, Aerni HR, et al. Molecular profiling of experimental parkinson’s disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry. J Proteome Res. 2004;3(2):289–295.
   PubMed Web of Science ®Google Scholar
• Stoeckli M, Staab D, Staufenbiel M, et al. Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry. Anal Biochem. 2002;311(1):33–39.
   PubMed Web of Science ®Google Scholar
• Schwartz SA, Weil RJ, Johnson MD, et al. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res. 2004;10(3):981–987.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang L, Zhang D, et al. Identification of potential serum biomarkers for wilms tumor after excluding confounding effects of common systemic inflammatory factors. Mol Biol Rep. 2012;39(5):5095–5104.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang X, Ge X, et al. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol. 2008;111(1):111–119.
   PubMed Web of Science ®Google Scholar
• Pallua JD, Schaefer G, Seifarth C, et al. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. J Proteomics. 2013;91:500–514.
   PubMed Web of Science ®Google Scholar
• Liu D, Cao L, Yu J, et al. 2009 Diagnosis of pancreatic adenocarcinoma using protein chip technology. Pancreatology. 2009;9(1-2):127–135.
   PubMed Web of Science ®Google Scholar
• Cornett DS, Mobley JA, Dias EC, et al. A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics. 2006;5(10):1975–1983.
   PubMed Web of Science ®Google Scholar
• Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2007;16(10):1935–1953.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhu J, He K, et al. Proteomic profiling of invasive ductal carcinoma (IDC) using magnetic beads-based serum fractionation and MALDI-TOF MS. J. Clin. Lab. Anal. 2015;29(4):321–327.
   PubMed Web of Science ®Google Scholar
• Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-Ica) in breast cancer tissue. Pathologe. 1987;8(3):138–140.
   PubMed Web of Science ®Google Scholar
• Vrioni G, Tsiamis C, Oikonomidis G, et al. MALDI-TOF mass spectrometry technology for detecting biomarkers of antimicrobial resistance: current achievements and future perspectives. Ann Transl Med. 2018;6(12):240.
   PubMed Web of Science ®Google Scholar
• Wisztorski M, Lemaire R, Stauber J, et al. New developments in MALDI imaging for pathology proteomic studies. Curr Pharm Des. 2007;13(32):3317–3324.
   PubMed Web of Science ®Google Scholar
• Xue B, Leyrat C, Grimes JM, et al. Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization. Proc Natl Acad Sci U S A. 2014;111(43):E4596–4605.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Qu C, Ge W, et al. Depletion of thymosin β4 promotes the proliferation, migration, and activation of human hepatic stellate cells. Cell Physiol Biochem. 2014;34(2):356–367.
   PubMedGoogle Scholar
• Kim S, Kwon J. Actin cytoskeletal rearrangement and dysfunction due to activation of the receptor for advanced glycation end products is inhibited by thymosin beta 4. J Physiol. 2015;593(8):1873–1886.
   PubMed Web of Science ®Google Scholar
• Crockford D, Turjman N, Allan C, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179–189.
   PubMed Web of Science ®Google Scholar
• Cierniewski CS, Papiewska-Pajak I, Malinowski M, et al. Thymosin beta4 regulates migration of Colon cancer cells by a pathway involving interaction with Ku80. Ann N Y Acad Sci. 2010;1194:60–71.
   PubMed Web of Science ®Google Scholar
• Hong KO, Lee JI, Hong SP, et al. Thymosin β4 induces proliferation, invasion, and epithelial-to-mesenchymal transition of oral squamous cell carcinoma. Amino Acids. 2016;48(1):117–127.
   PubMed Web of Science ®Google Scholar
• Trenkwalder T, Deindl E, Bongiovanni D, et al. Thymosin-β4-mediated therapeutic neovascularization: role of the PI3K/akt pathway. Expert Opin Biol Ther. 2015;15(sup1):175–185.
   PubMed Web of Science ®Google Scholar
• Yan F, He M, Hogan JM, et al. Targeted biomarker detection via whole protein ion trap tandem mass spectrometry: thymosin beta4 in a human lung cancer cell line. J Mass Spectrom. 2005;40(4):444–451.
   PubMed Web of Science ®Google Scholar
• Yoon SY, Lee HR, Park Y, et al. Thymosin β4 expression correlates with lymph node metastasis through hypoxia inducible factor-α induction in breast cancer. Oncol Rep. 2011;25(1):23–31.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Feurino LW, Zhai Q, et al. Thymosin beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther. 2008;7(3):419–423.
   PubMed Web of Science ®Google Scholar
• Tang MC, Chan LC, Yeh YC, et al. Thymosin beta 4 induces Colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway. Cancer Lett. 2011;308(2):162–171.
   PubMed Web of Science ®Google Scholar
• Oh JM, Moon EY. Actin-sequestering protein, thymosin beta-4, induces paclitaxel resistance through ROS/HIF-1alpha stabilization in HeLa human cervical tumor cells. Life Sci. 2010;87(9-10):286–293.
   PubMed Web of Science ®Google Scholar
• Huang H-C, Hu C-H, Tang M-C, et al. Thymosin beta4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. Oncogene. 2007;26(19):2781–2790.
   PubMed Web of Science ®Google Scholar
• Theunissen W, Fanni D, Nemolato S, et al. Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma. Eur J Histochem. 2014;58(1):2242.
   PubMed Web of Science ®Google Scholar
• Carlier MF, Hertzog M, Didry D, et al. Structure, function, and evolution of the beta-thymosin/WH2 (WASP-Homology2) actin-binding module. Ann N Y Acad Sci. 2007;1112:67–75.
   PubMed Web of Science ®Google Scholar
• Lee JW, Ryu YK, Ji YH, et al. Hypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1- and Rac1-GTPase activation via the expression of thymosin beta-4. Oncotarget. 2015;6(12):9820–9833.
   PubMedGoogle Scholar
• Moon EY, Im YS, Ryu YK, et al. Actin-sequestering protein, thymosin beta-4, is a novel hypoxia responsive regulator. Clin Exp Metastasis. 2010;27(8):601–609.
   PubMed Web of Science ®Google Scholar
• Hsiao HL, Wang WS, Chen PM, et al. Overexpression of thymosin beta-4 renders SW480 Colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating fas and upregulating survivin expression, respectively. Carcinogenesis. 2006;27(5):936–944.
   PubMed Web of Science ®Google Scholar
• Wang WS, Chen PM, Hsiao HL, et al. Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 Colon cancer cells. Oncogene. 2003;22(21):3297–3306.
   PubMed Web of Science ®Google Scholar
• Nemolato S, Restivo A, Cabras T, et al. Thymosin β 4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition. Cancer Biol Ther. 2012;13(4):191–197.
   PubMed Web of Science ®Google Scholar